PKU HealthCare (SZ:000788)2025-01-21 10:20Financial Projections - The estimated net profit for 2024 is projected to be between 115 million and 145 million CNY, representing a year-on-year growth of 159.26% to 226.90% compared to 44.36 million CNY in the previous year[3]. - The net profit after deducting non-recurring gains and losses is expected to be between 106 million and 136 million CNY, indicating a year-on-year increase of 167.42% to 243.11% from 39.64 million CNY last year[3]. - The basic earnings per share is forecasted to be between 0.1930 CNY and 0.2433 CNY, up from 0.0744 CNY in the same period last year[3]. - The performance forecast period is from January 1, 2024, to December 31, 2024[3]. Business Segments Performance - The growth in the pharmaceutical manufacturing segment is attributed to a focus on "anti-infection, analgesic, and psychiatric" areas, with significant market expansion and increased sales of key products[5]. - Key products such as Meropenem for injection, Buprenorphine Hydrochloride tablets, Cefotaxime Sodium for injection, and Ondansetron Hydrochloride tablets have seen increased sales, contributing to improved profitability[6]. - The pharmaceutical distribution segment benefited from rising demand in the downstream market, leading to increased revenue for the wholly-owned subsidiary Beijing Beiyuan Pharmaceutical Co., Ltd.[6]. Forecast Communication and Investor Advisory - The company has communicated its performance forecast with the auditing firm, and there are no discrepancies regarding the forecast[4]. - The performance forecast data is based on preliminary estimates by the company's finance department and will be detailed in the 2024 annual report[7]. - Investors are advised to make rational decisions and be aware of investment risks associated with the preliminary nature of the forecast[7].